Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 1 (2004), Issue 4 (November)

1. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies.
   Nat Rev Cancer, 4(11): 901-9. [Abstract] [Full-text]
2. Medical thoracoscopy: hormone receptor content in pleural metastases due to breast cancer.
   Eur Respir J, 24(5): 728-30. [Abstract] [Full-text]
3. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T.
   Radiology, 233(2): 424-31. [Abstract] [Full-text]
4. Protrusio acetabuli presenting as a complex pelvic mass after total hip arthroplasty.
   Obstet Gynecol, 104(5): 1187-9. [Abstract] [Full-text]
5. Index for spatial heterogeneity in breast cancer.
   J Microsc, 216: 110-22. [Abstract] [Full-text]
6. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.
   Nat Med, 10(11): 1251-6. [Abstract] [Full-text]
7. Positron emission tomography in the staging and management of breast cancer.
   Br J Surg, 91(11): 1398-409. [Abstract] [Full-text]
8. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
   J Surg Oncol, 88(2): 100-3. [Abstract] [Full-text]
9. Breast cancer metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and survival data.
   Radiology, 233(2): 400-9. [Abstract] [Full-text]
10. Women's satisfaction with genetic counseling for hereditary breast-ovarian cancer: psychological aspects.
    Am J Med Genet A, 131(1): 36-41. [Abstract] [Full-text]
11. Mutant BRCA1 alleles transmission: different approaches and different biases.
    Int J Cancer, 113(1): 166-7. [Abstract] [Full-text]
12. Feeling at risk: how women interpret their familial breast cancer risk.
    Am J Med Genet A, 131(1): 42-9. [Abstract] [Full-text]
13. Orbital metastases in breast cancer: report of two cases and review of the literature.
    J Cancer Res Clin Oncol, 130(12): 745-8. [Abstract] [Full-text]
14. Computer-aided detection performance in mammographic examination of masses: assessment.
    Radiology, 233(2): 418-23. [Abstract] [Full-text]
15. A mixture model-based strategy for selecting sets of genes in multiclass response microarray experiments.
    Bioinformatics, 20(16): 2562-71. [Abstract] [Full-text]
16. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2.
    Cancer Res, 64(21): 7947-53. [Abstract] [Full-text]
17. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins.
    Cancer Res, 64(21): 7886-92. [Abstract] [Full-text]
18. Alterations in vascular gene expression in invasive breast carcinoma.
    Cancer Res, 64(21): 7857-66. [Abstract] [Full-text]
19. From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies.
    Cancer Res, 64(21): 7748-55. [Abstract] [Full-text]
20. Mutation of the PIK3CA gene in ovarian and breast cancer.
    Cancer Res, 64(21): 7678-81. [Abstract] [Full-text]
21. Breast cancer cells isolated by chemotaxis from primary tumors show increased survival and resistance to chemotherapy.
    Cancer Res, 64(21): 7664-7. [Abstract] [Full-text]
22. PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer.
    Cancer Res, 64(21): 7655-60. [Abstract] [Full-text]
23. Risk factors for brain relapse in patients with metastatic breast cancer.
    Ann Oncol, 15(11): 1640-4. [Abstract] [Full-text]
24. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies.
    Ann Oncol, 15(11): 1633-9. [Abstract] [Full-text]
25. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.
    Ann Oncol, 15(11): 1627-32. [Abstract] [Full-text]
26. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?
    Ann Oncol, 15(11): 1622-6. [Abstract] [Full-text]
27. Cardiac chamber and coronary artery doses associated with postmastectomy radiotherapy techniques to the chest wall and regional nodes.
    Int J Radiat Oncol Biol Phys, 60(4): 1195-203. [Abstract] [Full-text]
28. Postmastectomy electron-beam chest-wall irradiation in women with breast cancer.
    Int J Radiat Oncol Biol Phys, 60(4): 1190-4. [Abstract] [Full-text]
29. Postmastectomy CT-based electron beam radiotherapy: dosimetry, efficacy, and toxicity in 118 patients.
    Int J Radiat Oncol Biol Phys, 60(4): 1182-9. [Abstract] [Full-text]
30. High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study.
    Int J Radiat Oncol Biol Phys, 60(4): 1173-81. [Abstract] [Full-text]
31. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy.
    Eur J Cancer, 40(16): 2509-18. [Abstract] [Full-text]
32. A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?
    Eur J Cancer, 40(16): 2474-9. [Abstract] [Full-text]
33. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
    Eur J Cancer, 40(16): 2432-8. [Abstract] [Full-text]
34. Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers.
    Eur J Cancer, 40(16): 2417-23. [Abstract] [Full-text]
35. Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer.
    Eur J Cancer, 40(16): 2403-10. [Abstract] [Full-text]
36. Surgery and outcomes of ductal carcinoma in situ of the breast: a population-based study in Australia.
    Eur J Cancer, 40(16): 2396-402. [Abstract] [Full-text]
37. The inhibitory effect of a herbal formula comprising ginseng and carthamus tinctorius on breast cancer.
    Life Sci, 76(2): 191-200. [Abstract] [Full-text]
38. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer.
    Surgery, 136(5): 1061-9. [Abstract] [Full-text]
39. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
    J Natl Cancer Inst, 96(21): 1593-603. [Abstract] [Full-text]
40. Fish intake, marine omega-3 fatty acids, and mortality in a cohort of postmenopausal women.
    Am J Epidemiol, 160(10): 1005-10. [Abstract] [Full-text]
41. Comparison of two-year and five-year tamoxifen use in Japanese post-menopausal women.
    Eur J Surg Oncol, 30(10): 1077-83. [Abstract] [Full-text]
42. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
    Eur J Surg Oncol, 30(10): 1069-76. [Abstract] [Full-text]
43. Radial scar, complex sclerosing lesion and risk of breast cancer. Analysis of 175 cases in Northern Ireland.
    Eur J Surg Oncol, 30(10): 1065-8. [Abstract] [Full-text]
44. Factors predisposing to cavity margin positivity following conservation surgery for breast cancer.
    Eur J Surg Oncol, 30(10): 1058-64. [Abstract] [Full-text]
45. Quality of life and health status in breast carcinoma.
    Eur J Surg Oncol, 30(10): 1051-7. [Abstract] [Full-text]
46. Estrogen receptor beta and breast cancer.
    Eur J Surg Oncol, 30(10): 1043-50. [Abstract] [Full-text]
47. Perceived breast cancer risk: heuristic reasoning and search for a dominance structure.
    Soc Sci Med, 60(2): 421-32. [Abstract] [Full-text]
48. Perioperative diagnosis of cystosarcoma phyllodes of the breast may be enhanced by MIB-1 index.
    J Surg Res, 122(1): 83-8. [Abstract] [Full-text]
49. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells.
    Chem Biol Interact, 150(1): 129-36. [Abstract] [Full-text]
50. Increased expression of geminin stimulates the growth of mammary epithelial cells and is a frequent event in human tumors.
    J Cell Physiol, 202(1): 215-22. [Abstract] [Full-text]
51. Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer.
    Ann Surg Oncol, 11(11): 1018-24. [Abstract] [Full-text]
52. Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors.
    Ann Surg Oncol, 11(11): 1011-7. [Abstract] [Full-text]
53. Intraoperative examination of sentinel nodes in breast cancer: is the glass half full or half empty?
    Ann Surg Oncol, 11(11): 1005-10. [Abstract] [Full-text]
54. Induction of apoptosis in human breast adenocarcinoma MCF-7 cells by prodelphinidin B-2 3,3'-di-O-gallate from Myrica rubra via Fas-mediated pathway.
    J Pharm Pharmacol, 56(11): 1399-406. [Abstract] [Full-text]
55. Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells.
    Oncogene, 23(52): 8557-62. [Abstract] [Full-text]
56. Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
    Oncogene, 23(52): 8535-44. [Abstract] [Full-text]
57. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
    Cancer Chemother Pharmacol, 54(6): 546-52. [Abstract] [Full-text]
58. Abnormal uterine bleeding as a presentation of metastatic breast disease in a patient with advanced breast cancer on tamoxifen therapy.
    Arch Gynecol Obstet, 270(3): 192-3. [Abstract] [Full-text]
59. Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines.
    Cancer Genet Cytogenet, 155(1): 57-62. [Abstract] [Full-text]
60. Preferential targeting of vesicular stomatitis virus to breast cancer cells.
    Virology, 330(1): 24-33. [Abstract] [Full-text]
61. Metastatic bone disease--the orthopaedic workload.
    Ann R Coll Surg Engl, 86(6): 436-8. [Abstract] [Full-text]
62. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer.
    Cancer Gene Ther, 11(11): 748-56. [Abstract] [Full-text]
63. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
    Cancer Gene Ther, 11(11): 757-66. [Abstract] [Full-text]
64. All trans-retinoic acid acts synergistically with hydroxytamoxifen and transforming-growth factor beta to stimulate apoptosis in MCF-7 breast cancer cells.
    J Endocrinol, 183(2): 395-404. [Abstract] [Full-text]
65. Partial breast irradiation: revolution or evolution?
    Cancer Treat Rev, 30(7): 599-607. [Abstract] [Full-text]
66. Neurofibroma of the breast in a boy with neurofibromatosis type 1.
    Clin Imaging, 28(6): 415-7. [Abstract] [Full-text]
67. Postmenopausal testosterone therapy and breast cancer risk.
    Maturitas, 49(4): 267-75. [Abstract] [Full-text]
68. Retinoids arrest breast cancer cell proliferation: retinoic acid selectively reduces the duration of receptor tyrosine kinase signaling.
    Exp Cell Res, 301(2): 147-57. [Abstract] [Full-text]
69. The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis.
    Exp Cell Res, 301(2): 103-18. [Abstract] [Full-text]
70. Efficacy of cognitive therapy for depression among women with metastatic cancer: a single-case experimental study.
    J Behav Ther Exp Psychiatry, 35(4): 287-305. [Abstract] [Full-text]
71. A combined breast health/weight loss intervention for Black women.
    Prev Med, 40(4): 373-83. [Abstract] [Full-text]
72. Evaluation of pathways for progression of heterogeneous breast tumors.
    J Theor Biol, 232(2): 179-89. [Abstract] [Full-text]
73. Intraductal biopsy for diagnosis and treatment of intraductal lesions of the breast.
    Cancer, 101(10): 2164-9. [Abstract] [Full-text]
74. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations.
    Cancer, 101(10): 2327-40. [Abstract] [Full-text]
75. Treatment of breast carcinoma in patients with clinically negative axillary lymph nodes using radiotherapy versus axillary dissection.
    Cancer, 101(10): 2155-63. [Abstract] [Full-text]
76. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative.
    J Biol Chem, 279(46): 48071-8. [Abstract] [Full-text]
77. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Clin Cancer Res, 10(21): 7375-81. [Abstract] [Full-text]
78. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Clin Cancer Res, 10(21): 7335-46. [Abstract] [Full-text]
79. Prognostic value of ERM gene expression in human primary breast cancers.
    Clin Cancer Res, 10(21): 7297-303. [Abstract] [Full-text]
80. Mouse mammary tumor virus-like RNA transcripts and DNA are found in affected cells of human breast cancer.
    Clin Cancer Res, 10(21): 7284-9. [Abstract] [Full-text]
81. Angiogenic profile of breast carcinoma determines leukocyte infiltration.
    Clin Cancer Res, 10(21): 7171-8. [Abstract] [Full-text]
82. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
    Clin Cancer Res, 10(21): 7157-62. [Abstract] [Full-text]
83. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer.
    Clin Cancer Res, 10(21): 7144-9. [Abstract] [Full-text]
84. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
    Clin Cancer Res, 10(21): 7136-43. [Abstract] [Full-text]
85. Metabolism of the microregions of human breast cancer.
    Cancer Lett, 216(2): 243-8. [Abstract] [Full-text]
86. Comparison of FNAC and open biopsy in palpable breast lumps.
    J Coll Physicians Surg Pak, 14(11): 654-6. [Abstract] [Full-text]
87. An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
    Health Serv Res, 39(6): 1733-49. [Abstract] [Full-text]
88. Mammography screening in the Netherlands: delay in the diagnosis of breast cancer after breast cancer screening.
    Br J Cancer, 91(10): 1795-9. [Abstract] [Full-text]
89. Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer.
    Br J Cancer, 91(10): 1813-20. [Abstract] [Full-text]
90. Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort.
    Br J Cancer, 91(10): 1787-94. [Abstract] [Full-text]
91. Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity.
    Br J Cancer, 91(10): 1821-8. [Abstract] [Full-text]
92. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin.
    Br J Cancer, 91(10): 1800-7. [Abstract] [Full-text]
93. The impact of preoperative breast biopsy on the risk of sentinel lymph node metastases: analysis of 2502 cases from the Austrian Sentinel Node Biopsy Study Group.
    Br J Cancer, 91(10): 1782-6. [Abstract] [Full-text]
94. Multiplexed fluorescence detection of phosphorylation, glycosylation, and total protein in the proteomic analysis of breast cancer refractoriness.
    Proteomics, 4(11): 3464-7. [Abstract] [Full-text]
95. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.
    Breast Cancer Res Treat, 88(1): 75-85. [Abstract] [Full-text]
96. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Breast Cancer Res Treat, 88(1): 63-73. [Abstract] [Full-text]
97. Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk.
    Breast Cancer Res Treat, 88(1): 55-62. [Abstract] [Full-text]
98. Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women.
    Breast Cancer Res Treat, 88(1): 49-54. [Abstract] [Full-text]
99. Clinical experience with axillary presentation breast cancer.
    Breast Cancer Res Treat, 88(1): 43-7. [Abstract] [Full-text]
100. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
     Breast Cancer Res Treat, 88(1): 29-41. [Abstract] [Full-text]
101. Expression of FGF-2 alters focal adhesion dynamics in migration-restricted MDA-MB-231 breast cancer cells.
     Breast Cancer Res Treat, 88(1): 17-28. [Abstract] [Full-text]
102. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
     Breast Cancer Res Treat, 88(1): 9-16. [Abstract] [Full-text]
103. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
     Breast Cancer Res Treat, 88(1): 1-8. [Abstract] [Full-text]
104. NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer.
     Oncogene, 23(53): 8681-7. [Abstract] [Full-text]
105. Cancer risk-reduction behaviors of breast cancer survivors.
     West J Nurs Res, 26(8): 872-90. [Abstract] [Full-text]
106. Concentrated smear technique for examining sentinel lymph nodes of the breast at the time of frozen section.
     Am J Clin Pathol, 122(6): 944-6. [Abstract] [Full-text]
107. Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications.
     J Clin Oncol, 22(22): 4507-13. [Abstract] [Full-text]
108. Cell-type-dependent effect of transforming growth factor beta, a major cytokine in breast milk, on human immunodeficiency virus type 1 infection of mammary epithelial MCF-7 cells or macrophages.
     J Virol, 78(23): 13046-52. [Abstract] [Full-text]
109. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.
     Cancer Cell, 6(5): 459-69. [Abstract] [Full-text]
110. A new key in breast cancer metastasis.
     Cancer Cell, 6(5): 429-30. [Abstract] [Full-text]
111. Intensity modulated radiation therapy with electrons using algorithm based energy/range selection methods.
     Radiother Oncol, 73(2): 223-31. [Abstract] [Full-text]
112. Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.
     Radiother Oncol, 73(2): 133-9. [Abstract] [Full-text]
113. Factors that affect breast cancer treatment: underserved and minority populations.
     Surg Oncol Clin N Am, 14(1): 119-30, vii. [Abstract] [Full-text]
114. The quality of early-stage breast cancer treatment: what can we do to improve?
     Surg Oncol Clin N Am, 14(1): 103-17, vi. [Abstract] [Full-text]
115. Breast cancer treatment in older women.
     Surg Oncol Clin N Am, 14(1): 85-102, vi. [Abstract] [Full-text]
116. Beyond lymph node staging: molecular predictors of outcome in breast cancer.
     Surg Oncol Clin N Am, 14(1): 69-84, vi. [Abstract] [Full-text]
117. Ductal lavage for breast cancer risk assessment.
     Surg Oncol Clin N Am, 14(1): 45-68, vi. [Abstract] [Full-text]
118. Nonsurgical ablation of primary breast cancer.
     Surg Oncol Clin N Am, 14(1): 33-44. [Abstract] [Full-text]
119. Immunologic approaches to breast cancer treatment.
     Surg Oncol Clin N Am, 14(1): 1-31, v. [Abstract] [Full-text]
120. Interactive detection and visualization of breast lesions from dynamic contrast enhanced MRI volumes.
     Comput Med Imaging Graph, 28(8): 435-44. [Abstract] [Full-text]
121. Estrogen regulation of trefoil factor 1 expression by estrogen receptor alpha and Sp proteins.
     Exp Cell Res, 302(1): 96-107. [Abstract] [Full-text]
122. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
     Cancer Treat Rev, 30(8): 695-706. [Abstract] [Full-text]
123. Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation.
     Cancer Treat Rev, 30(8): 671-82. [Abstract] [Full-text]
124. alpha-Trinositol inhibits FGF-stimulated growth of smooth muscle and breast cancer cells.
     Biochem Biophys Res Commun, 325(3): 691-7. [Abstract] [Full-text]
125. Differential protein acetylation induced by novel histone deacetylase inhibitors.
     Biochem Biophys Res Commun, 325(3): 683-90. [Abstract] [Full-text]
126. Male breast cancer--an andrological disease: risk factors and diagnosis.
     Andrologia, 36(6): 346-54. [Abstract] [Full-text]
127. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
     J Clin Oncol, 22(22): 4456-62. [Abstract] [Full-text]
128. Effect on oximetry of dyes used for sentinel lymph node biopsy.
     Arch Surg, 139(11): 1204-7. [Abstract] [Full-text]
129. Specific enkephalin-degrading aminopeptidase activity in the HPT and HPO axes of rats with breast cancer induced by N-methyl nitrosourea.
     Regul Pept, 124(1): 157-61. [Abstract] [Full-text]
130. Self-reported use of shared decision-making among breast cancer specialists and perceived barriers and facilitators to implementing this approach.
     Health Expect, 7(4): 338-48. [Abstract] [Full-text]
131. Suffering related to health care: a study of breast cancer patients' experiences.
     Int J Nurs Pract, 10(6): 248-56. [Abstract] [Full-text]
132. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.
     Mod Pathol, 17(12): 1545-54. [Abstract] [Full-text]
133. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.
     Ann Oncol, 15(12): 1834-41. [Abstract] [Full-text]
134. Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
     Ann Oncol, 15(12): 1760-5. [Abstract] [Full-text]
135. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93.
     Ann Oncol, 15(12): 1749-59. [Abstract] [Full-text]
136. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
     Ann Oncol, 15(12): 1738-47. [Abstract] [Full-text]
137. The professional role of breast cancer nurses in multi-disciplinary breast cancer care teams.
     Eur J Oncol Nurs, 8(4): 306-14. [Abstract] [Full-text]
138. The importance of place of residence in predicting late-stage diagnosis of breast or cervical cancer.
     Health Place, 11(1): 15-29. [Abstract] [Full-text]
139. A tailored intervention to promote breast cancer screening among South Asian immigrant women.
     Soc Sci Med, 60(3): 575-86. [Abstract] [Full-text]
140. Oestrogen receptors revisited: long-term follow up of over five thousand breast cancer patients.
     ANZ J Surg, 74(11): 957-60. [Abstract] [Full-text]
141. Internal mammary nodes in invasive breast carcinoma. To treat or not to treat?
     Strahlenther Onkol, 180(11): 690-4. [Abstract] [Full-text]
142. Ductal carcinoma in situ of the breast. Increasing importance of radiotherapy as a part of the therapy approach.
     Strahlenther Onkol, 180(11): 682-9. [Abstract] [Full-text]
143. The use of IL-2 cultures to measure chromosomal radiosensitivity in breast cancer patients.
     Mutagenesis, 19(6): 493-8. [Abstract] [Full-text]
144. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin.
     Cancer Res, 64(22): 8381-8. [Abstract] [Full-text]
145. P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells.
     Cancer Res, 64(22): 8309-17. [Abstract] [Full-text]
146. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells.
     Cancer Res, 64(22): 8299-308. [Abstract] [Full-text]
147. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer.
     Cancer Res, 64(22): 8184-92. [Abstract] [Full-text]
148. Significant contribution of germline BRCA2 rearrangements in male breast cancer families.
     Cancer Res, 64(22): 8143-7. [Abstract] [Full-text]
149. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers.
     Acta Obstet Gynecol Scand, 83(12): 1104-11. [Abstract] [Full-text]
150. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
     J Natl Cancer Inst, 96(22): 1676-81. [Abstract] [Full-text]
151. The role of BRCA1 in the cellular response to chemotherapy.
     J Natl Cancer Inst, 96(22): 1659-68. [Abstract] [Full-text]
152. Diagnostic criteria for psychosomatic research and psychosocial variables in breast cancer patients.
     Psychosomatics, 45(6): 483-91. [Abstract] [Full-text]
153. Reliability of X-rays and bone scans for the assessment of changes in skeletal metastases from breast cancer.
     Intern Med J, 34(11): 615-20. [Abstract] [Full-text]
154. Repression and high anxiety are associated with aberrant diurnal cortisol rhythms in women with metastatic breast cancer.
     Health Psychol, 23(6): 645-50. [Abstract] [Full-text]
155. Finding benefit in breast cancer during the year after diagnosis predicts better adjustment 5 to 8 years after diagnosis.
     Health Psychol, 23(6): 595-8. [Abstract] [Full-text]
156. Relationship of social support and social burden to repeated breast cancer screening in the women's health initiative.
     Health Psychol, 23(6): 582-94. [Abstract] [Full-text]
157. A longitudinal analysis of the course of depressive symptomatology in geriatric patients with cancer of the breast, colon, lung, or prostate.
     Health Psychol, 23(6): 564-73. [Abstract] [Full-text]
158. Comparison of three different staining techniques for intraoperative assessment of nodal metastasis in breast cancer.
     Diagn Cytopathol, 31(6): 423-6. [Abstract] [Full-text]
159. Fine-needle aspiration diagnosis of plasmacytoma presenting as breast masses in a patient on estrogen therapy for prostate cancer.
     Diagn Cytopathol, 31(6): 417-9. [Abstract] [Full-text]
160. Columnar cell lesions: fine-needle aspiration biopsy features.
     Diagn Cytopathol, 31(6): 370-5. [Abstract] [Full-text]
161. Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5.
     J Cell Biochem, 93(6): 1134-42. [Abstract] [Full-text]
162. Profound changes in breast cancer incidence may reflect changes into a Westernized lifestyle: a comparative population-based study in Singapore and Sweden.
     Int J Cancer, 113(2): 302-6. [Abstract] [Full-text]
163. Insulin-like growth factor-I gene polymorphism and breast cancer risk in Chinese women.
     Int J Cancer, 113(2): 307-11. [Abstract] [Full-text]
164. Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study.
     Cancer, 102(5): 322-7. [Abstract] [Full-text]
165. Exercise therapy in women who have had breast cancer: design of the Sheffield women's exercise and well-being project.
     Health Educ Res, 19(6): 686-97. [Abstract] [Full-text]
166. Sentinel lymph node biopsy progress in surgical treatment of cancer.
     Langenbecks Arch Surg, 389(6): 532-50. [Abstract] [Full-text]
167. Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients.
     Int J Qual Health Care, 16(6): 517-21. [Abstract] [Full-text]
168. Nucleolar size and activity are related to pRb and p53 status in human breast cancer.
     J Histochem Cytochem, 52(12): 1601-7. [Abstract] [Full-text]
169. Assessing the impact of CAD on the sensitivity and specificity of film readers.
     Clin Radiol, 59(12): 1099-105. [Abstract] [Full-text]
170. Patterns of metastatic breast carcinoma: influence of tumour histological grade.
     Clin Radiol, 59(12): 1094-8. [Abstract] [Full-text]
171. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.
     J Am Coll Surg, 199(6): 856-62. [Abstract] [Full-text]
172. Cellular aging of mitochondrial DNA-depleted cells.
     Biochem Biophys Res Commun, 325(4): 1399-405. [Abstract] [Full-text]
173. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences.
     Psychooncology, 13(11): 769-78. [Abstract] [Full-text]
174. Supportive-expressive group therapy: the transformation of existential ambivalence into creative living while enhancing adherence to anti-cancer therapies.
     Psychooncology, 13(11): 755-68. [Abstract] [Full-text]
175. Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells.
     J Pharmacol Exp Ther, 311(3): 1032-7. [Abstract] [Full-text]
176. Single-injection paravertebral block before general anesthesia enhances analgesia after breast cancer surgery with and without associated lymph node biopsy.
     Anesth Analg, 99(6): 1837-43, table of contents. [Abstract] [Full-text]
177. Association of body composition and weight history with breast cancer prognostic markers: divergent pattern for Hispanic and non-Hispanic White women.
     Am J Epidemiol, 160(11): 1087-97. [Abstract] [Full-text]
178. Job stress and breast cancer risk: the nurses' health study.
     Am J Epidemiol, 160(11): 1079-86. [Abstract] [Full-text]
179. Refugee women's reproductive health in early resettlement.
     J Obstet Gynecol Neonatal Nurs, 33(6): 723-8. [Abstract] [Full-text]
180. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.
     Br J Cancer, 91(11): 1893-901. [Abstract] [Full-text]
181. A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma.
     Cancer, 101(11): 2516-22. [Abstract] [Full-text]
182. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma.
     Cancer, 101(11): 2701-8. [Abstract] [Full-text]
183. Racial differences in knowledge, attitudes, and cancer screening practices among a triracial rural population.
     Cancer, 101(11): 2650-9. [Abstract] [Full-text]
184. A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy.
     Cancer, 101(11): 2509-15. [Abstract] [Full-text]
185. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
     Mol Pharmacol, 66(6): 1478-90. [Abstract] [Full-text]
186. Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells.
     Mol Endocrinol, 18(12): 2937-49. [Abstract] [Full-text]
187. Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells.
     Mol Endocrinol, 18(12): 3064-75. [Abstract] [Full-text]
188. A digital atlas of breast histopathology: an application of web based virtual microscopy.
     J Clin Pathol, 57(12): 1288-91. [Abstract] [Full-text]
189. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage.
     J Biol Chem, 279(49): 51323-30. [Abstract] [Full-text]
190. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines.
     J Cancer Res Clin Oncol, 131(1): 41-8. [Abstract] [Full-text]
191. A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer.
     Breast Cancer Res Treat, 88(2): 187-96. [Abstract] [Full-text]
192. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
     Breast Cancer Res Treat, 88(2): 177-86. [Abstract] [Full-text]
193. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis.
     Breast Cancer Res Treat, 88(2): 161-76. [Abstract] [Full-text]
194. Distinct incidence patterns among in situ and invasive breast carcinomas,with possible etiologic implications.
     Breast Cancer Res Treat, 88(2): 149-59. [Abstract] [Full-text]
195. Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas.
     Breast Cancer Res Treat, 88(2): 131-9. [Abstract] [Full-text]
196. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
     Breast Cancer Res Treat, 88(2): 117-29. [Abstract] [Full-text]
197. Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
     Breast Cancer Res Treat, 88(2): 109-16. [Abstract] [Full-text]
198. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
     Breast Cancer Res Treat, 88(2): 103-8. [Abstract] [Full-text]
199. Ureteral metastasis of occult breast cancer.
     Breast, 13(6): 530-2. [Abstract] [Full-text]
200. Management of neuroendocrine differentiated breast carcinoma.
     Breast, 13(6): 527-9. [Abstract] [Full-text]
201. Lymphoepithelioma-like carcinoma of the breast: is it a distinct entity? Clinicopathological evaluation of two cases and review of the literature.
     Breast, 13(6): 522-6. [Abstract] [Full-text]
202. Invasive ductal carcinoma with tissue neutrophilia: a distinct entity?
     Breast, 13(6): 519-21. [Abstract] [Full-text]
203. Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer.
     Breast, 13(6): 515-8. [Abstract] [Full-text]
204. Glycogen-rich clear cell mammary malignant myoepithelioma.
     Breast, 13(6): 506-9. [Abstract] [Full-text]
205. Wise pattern mastectomy with immediate breast reconstruction.
     Breast, 13(6): 502-5. [Abstract] [Full-text]
206. A decision aid for predicting non-sentinel node involvement in women with breast cancer and at least one positive sentinel node.
     Breast, 13(6): 494-501. [Abstract] [Full-text]
207. Skin-sparing mastectomy and immediate breast reconstruction: incidence of recurrence in patients with invasive breast cancer.
     Breast, 13(6): 488-93. [Abstract] [Full-text]
208. A needle-localised open-breast biopsy for nonpalpable breast lesions should not be performed for diagnosis.
     Breast, 13(6): 476-82. [Abstract] [Full-text]
209. Breast cancer management: the perspective of general practitioners in inner and eastern Melbourne.
     Breast, 13(6): 468-75. [Abstract] [Full-text]
210. Ductal carcinoma in situ presenting as microcalcifications: the effect of stereotactic large-core needle biopsy on surgical therapy.
     Breast, 13(6): 461-7. [Abstract] [Full-text]
211. Radioresistance in carcinoma of the breast.
     Breast, 13(6): 452-60. [Abstract] [Full-text]
212. Tamoxifen and pregnancy.
     Breast, 13(6): 446-51. [Abstract] [Full-text]
213. Small hypoattenuating hepatic lesions at contrast-enhanced CT: prognostic importance in patients with breast cancer.
     Radiology, 233(3): 667-73. [Abstract] [Full-text]
214. Follow-up of palpable circumscribed noncalcified solid breast masses at mammography and US: can biopsy be averted?
     Radiology, 233(3): 850-6. [Abstract] [Full-text]
215. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.
     Radiology, 233(3): 830-49. [Abstract] [Full-text]
216. Fibronectin and type IV collagen activate ERalpha AF-1 by c-Src pathway: effect on breast cancer cell motility.
     Oncogene, 23(55): 8920-30. [Abstract] [Full-text]
217. Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer.
     Oncogene, 23(55): 8959-70. [Abstract] [Full-text]
218. Expression of e-cadherin in high-risk breast cancer.
     J Cancer Res Clin Oncol, 131(1): 14-8. [Abstract] [Full-text]
219. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
     Int J Cancer, 113(3): 364-71. [Abstract] [Full-text]
220. Do nonattenders in mammography screening programmes seek mammography elsewhere?
     Int J Cancer, 113(3): 464-70. [Abstract] [Full-text]
221. Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility.
     Int J Cancer, 113(3): 345-53. [Abstract] [Full-text]
222. Serum testosterone levels and breast cancer recurrence.
     Int J Cancer, 113(3): 499-502. [Abstract] [Full-text]
223. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
     Cancer Chemother Pharmacol, 55(1): 21-32. [Abstract] [Full-text]
224. Small (< 2.0-cm) breast cancers: mammographic and US findings at US-guided cryoablation--initial experience.
     Radiology, 233(3): 857-67. [Abstract] [Full-text]
225. Active recruitment increased enrollment in a hereditary cancer registry.
     J Clin Epidemiol, 57(11): 1172-6. [Abstract] [Full-text]
226. The relation of breast cancer staging to screening protocol compliance: a computer simulation study.
     Comput Biol Med, 35(2): 91-101. [Abstract] [Full-text]
227. Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses.
     Biochem Biophys Res Commun, 326(1): 218-27. [Abstract] [Full-text]
228. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
     Liver Int, 24(6): 540-6. [Abstract] [Full-text]
229. Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin-C enhances matrix metalloproteinase-9 expression and cancer cell invasion.
     Int J Exp Pathol, 85(6): 373-9. [Abstract] [Full-text]
230. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
     J Clin Oncol, 22(23): 4691-9. [Abstract] [Full-text]
231. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
     J Clin Oncol, 22(23): 4683-90. [Abstract] [Full-text]
232. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice.
     Clin Cancer Res, 10(22): 7703-11. [Abstract] [Full-text]
233. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression.
     Clin Cancer Res, 10(22): 7637-44. [Abstract] [Full-text]
234. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
     Clin Cancer Res, 10(22): 7621-8. [Abstract] [Full-text]
235. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
     Clin Cancer Res, 10(22): 7583-91. [Abstract] [Full-text]
236. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid.
     Clin Cancer Res, 10(22): 7500-10. [Abstract] [Full-text]
237. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
     Clin Cancer Res, 10(22): 7490-9. [Abstract] [Full-text]
238. Dendritic cell infiltration and prognosis of early stage breast cancer.
     Clin Cancer Res, 10(22): 7466-74. [Abstract] [Full-text]
239. Hippocampal volume and first major depressive episode after cancer diagnosis in breast cancer survivors.
     Am J Psychiatry, 161(12): 2263-70. [Abstract] [Full-text]
240. Intramedullary spinal cord metastasis in breast cancer: clinical features, diagnosis, and therapeutic consideration.
     Breast J, 10(6): 532-5. [Abstract] [Full-text]
241. Granular cell tumor of the breast: a series of 17 cases and review of the literature.
     Breast J, 10(6): 528-31. [Abstract] [Full-text]
242. Observations on the pathologic diagnosis of selected unusual lesions in needle core biopsies of breast.
     Breast J, 10(6): 522-7. [Abstract] [Full-text]
243. Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan.
     Breast J, 10(6): 509-13. [Abstract] [Full-text]
244. Dual-frequency ultrasound examination of skin and subcutis thickness in breast cancer-related lymphedema.
     Breast J, 10(6): 496-503. [Abstract] [Full-text]
245. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid.
     Breast J, 10(6): 492-5. [Abstract] [Full-text]
246. The negative predicative value of breast fine-needle aspiration biopsy: the Massachusetts General Hospital experience.
     Breast J, 10(6): 487-91. [Abstract] [Full-text]
247. Use of alternative therapy in postmenopausal breast cancer patients treated with tamoxifen after surgery.
     Breast J, 10(6): 481-6. [Abstract] [Full-text]
248. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
     Breast J, 10(6): 475-80. [Abstract] [Full-text]
249. Photoacoustic mammography laboratory prototype: imaging of breast tissue phantoms.
     J Biomed Opt, 9(6): 1172-81. [Abstract] [Full-text]
250. Improved quantification of small objects in near-infrared diffuse optical tomography.
     J Biomed Opt, 9(6): 1161-71. [Abstract] [Full-text]
251. Near-infrared imaging of the human breast: complementing hemoglobin concentration maps with oxygenation images.
     J Biomed Opt, 9(6): 1152-60. [Abstract] [Full-text]
252. Intraoperatively assessed optical properties of malignant and healthy breast tissue used to determine the optimum wavelength of contrast for optical mammography.
     J Biomed Opt, 9(6): 1129-36. [Abstract] [Full-text]
253. Elastic scattering spectroscopy for intraoperative determination of sentinel lymph node status in the breast.
     J Biomed Opt, 9(6): 1122-8. [Abstract] [Full-text]
254. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
     J Clin Oncol, 22(23): 4622-30. [Abstract] [Full-text]
255. Type V collagen regulates the expression of apoptotic and stress response genes by breast cancer cells.
     J Cell Physiol, 202(2): 411-21. [Abstract] [Full-text]
256. Caspase-3 inhibits the growth of breast cancer cells independent of protease activity.
     J Cell Physiol, 202(2): 478-82. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.